Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.37 |
| ▸ | USP2 | O75604 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | PDE9A | O76083 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598920 | 0.91 | TSHR (0.40) | TSHRCYP1A2CYP3A4CYP2C19USP2 | |
| SCHEMBL12598927 | 0.82 | ALDH1A1 (0.35) | ALDH1A1HSD17B10MAPK1LMNAMAPT | |
| SCHEMBL692065 | 0.79 | NPC1 (0.36) | ALDH1A1HSD17B10MAPK1LMNAMAPT | |
| SCHEMBL691247 | 0.79 | RAB9A (0.38) | CYP1A2CYP3A4CYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL1770538 | 0.78 | PIK3CG (0.36) | CYP3A4ALDH1A1LMNAMAPTPOLB | |
| SCHEMBL12598928 | 0.77 | NOX1 (0.38) | CYP1A2CYP3A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL693891 | 0.76 | MAPT (0.37) | CYP1A2CYP3A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL1770530 | 0.75 | HCAR3 (0.41) | ALDH1A1HSD17B10MAPK1LMNAMAPT | |
| SCHEMBL1770533 | 0.75 | HCAR3 (0.38) | TSHRALDH1A1HSD17B10MAPK1LMNA | |
| SCHEMBL693037 | 0.74 | HCAR3 (0.39) | ALDH1A1HSD17B10MAPK1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421871-B1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-09-16 | — | — | EP | disclosed |
| EP-2421871-B1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2421871-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| WO-2010122071-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122071-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | CCNA1, MKI67, CCNT1 | TSHR 53/4885CYP1A2 91/4885CYP3A4 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.